Last reviewed · How we verify
Nitrous Oxide 99 %
Nitrous oxide acts as a dissociative anesthetic and analgesic by antagonizing N-methyl-D-aspartate (NMDA) receptors in the central nervous system.
Nitrous oxide acts as a non-competitive antagonist at the N-methyl-D-aspartate (NMDA) receptor, producing dissociative anesthesia and analgesia. Used for Anesthesia (induction and maintenance), Analgesia for acute pain and dental procedures, Anxiolysis.
At a glance
| Generic name | Nitrous Oxide 99 % |
|---|---|
| Sponsor | Unity Health Toronto |
| Drug class | Inhalational anesthetic |
| Target | NMDA receptor |
| Modality | Small molecule |
| Therapeutic area | Anesthesia |
| Phase | FDA-approved |
Mechanism of action
Nitrous oxide binds to NMDA receptors and inhibits their function, leading to dissociation, analgesia, and mild anesthesia. It has rapid onset and offset due to its low blood solubility and is commonly used in combination with other anesthetics or analgesics for procedural sedation and pain relief. The drug does not significantly depress respiratory or cardiovascular function at sub-anesthetic doses.
Approved indications
- Analgesia and sedation during surgical and dental procedures
- Acute pain relief in emergency and prehospital settings
- Anxiolysis during medical procedures
Common side effects
- Dizziness or lightheadedness
- Nausea and vomiting
- Headache
- Dissociation or altered mental status
- Vitamin B12 depletion with chronic use
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |